We hypothesized a subgroup of CRC tumors may be sensitive to treatment with the combination of MEK and SRC inhibitors and can be selected utilizing gene expression signatures translated into quantitative biomarker scores. This evidence concerns the gene MAP2K7 and colorectal carcinoma.